Figure 6.

Effect of therapeutically administered AQX‐1125 on bleomycin‐induced body weight loss and survival. Mice were treated with either saline vehicle (sal, p.o., daily), AQX‐1125 (3, 10 or 30 mg·kg⁻¹·d⁻¹, p.o.) or pirfenidone (pirf, 90 mg·kg⁻¹·d⁻¹, p.o.) starting on Day 13 (indicated by ↑) after receiving a single intratracheal administration of bleomycin (BLM). The sham‐treated group received intratracheal saline. Body weights were measured throughout the study and normalized to the starting weight at Day 0 (100%), in order to visualize the percent change over 28 days (A). Mean survival was also plotted for each group following the initiation of treatment (B) with the number of remaining animals shown for each group in the period prior to compound treatment and following initiation of dosing (C). *P < 0.05, significantly different from vehicle using a log‐rank test. All bleomycin‐treated groups had n = 40 at Day 0.